Drug
Qls5133 Lenvatinib
Qls5133 Lenvatinib: highest development phase Phase 1/2, developed by Qilu Pharmaceutical Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Qilu Pharmaceutical Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| QLS5133; Lenvatinib mesylate NCT07933419 | Phase 1/2 | Clear Cell Renal Cell Carcinoma |
Latest
No recent events.
Follow Qls5133 Lenvatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.